GlassScriptPhysician profile
Sydnee Torrence Weber
NPI 1386124881
$2,295.49
in general payments reported to CMS, 2019-2025
20 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $183 · 2024: $550 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $649.04 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $340.90 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $248.97 | 2025 | Uzedy, Austedo Xr |
| Lundbeck LLC | $154.39 | 2024-2025 | Rexulti |
| Pfizer INC. | $142.96 | 2023-2024 | |
| Abbvie INC. | $121.96 | 2023-2025 | |
| Alkermes, INC. | $91.72 | 2024-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $90.66 | 2024-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $68.69 | 2025 | |
| Exact Sciences Corporation | $66.31 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.57 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $47.60 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Lilly USA, LLC | $43.81 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Bausch Health US, LLC | $39.38 | 2025 | Aplenzin |
| Axsome Therapeutics, INC. | $34.12 | 2025 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $32.45 | 2024 | Farxiga, Breztri |
| Supernus Pharmaceuticals, INC. | $19.80 | 2025 | Qelbree |
| Novo Nordisk INC | $17.14 | 2023 | Rybelsus |
| Seqirus USA INC | $17.00 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Medicomp INC | $16.02 | 2024 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydnee Torrence Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.